Schmerzmedizin 3 / 2019

Literatur 1. Steiner TJ et al. Migraine: the seventh disabler. Cephalalgia 2013;33:289-90 2. Steiner TJ et al. The impact of headache in Europe: principal results of the Eurolight project. J Headache Pain 2014;15:31 3. Göbel H. Die Kopfschmerzen. 3. Ausgabe. Berlin, Heidelberg: Springer; 2012 4. Hagen K et al. Headache as a risk factor for dementia: a prospective population-based study. Cephalalgia 2014;34:327-35 5. GBD 2016 Disease and injury incidence and prevalence collaborators. global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1211- 59 6. Steiner TJ et al. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain 2018;19:17 7. Wang SJ et al. Comorbidities of migraine. Front Neurol 2010;1:16 8. Hu X et al. Migraine and the risk of stroke: an updated meta-analysis of prospective cohort studies. Neurol Sci 2017;38:33-40 9. Linde M et al. The cost of headache disorders in Europe: the Eurolight project. Eur J Neurol 2012;19:703-11 10. Goadsby PJ et al. Pathophysiology of migraine: A disorder of sensory processing. Physiol Rev 2017;97:553-622 11. Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol 2018;17:174-82 12. Dodick DW. A phase-by-phase review of migraine pathophysiology. Headache 2018;58:Suppl 1:4-16 13. Ong JJY et al. Recent advances in pharmacotherapy for migraine prevention: from pathophysiology to new drugs. Drugs 2018;78:411-37 14. Ashina H et al. CGRP in human models of migraine. Handb Exp Pharmacol. online 13. Juni 2018 doi:10.1007/164_2018_128 15. Edvinsson L (2018) The CGRP pathway in migraine as a viable target for therapies. Headache 58 Suppl 1:33-47 16. Edvinsson L et al. CGRP as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol 2018;14:338-50 17. Holland PR. Foreword: The CGRP pathway and migraine prevention: reducing the burden of disease. Headache 2018;58 Suppl 1:1-3 18. Maasumi K et al. CGRP and migraine: The role of blocking Calcitonin Gene-Related Peptide ligand and receptor in the management of migraine. Drugs 2018;78:913-28 19. Messina R et al. CGRP - a target for acute therapy in migraine: Clinical data. Cephalalgia 2019;39:420-7 20. Cauchi M et al. CGRP and migraine. J Neurol 2016;263:192-4 21. Deen M et al. Blocking CGRP in migraine patients - a review of pros and cons. J Headache Pain 2017;18:96 doi:10.1186/ s10194-017-0807-1 22. Edvinsson L. The journey to establish CGRP as a migraine target: A retrospective view. Headache 2015;55:1249-55 23. Fiala JL et al. Patent watch: Migraine therapies targeting the CGRP pathway: intellectual property landscape. Nat Rev Drug Discov 2016;15:8-9 24. Karsan N et al. CGRP mechanism antagonists and migraine management. Curr Neurol Neurosci Rep 2015;15:25 25. Khan S et al. CGRP, a target for preventive therapy in migraine and cluster headache: Systematic review of clinical data. Cephalalgia 2019;39:374-89 26. Wrobel Goldberg S et al. Targeting CGRP: A new era for migraine treatment. CNS Drugs 2015;29:443-52 27. Yuan H et al. CGRP monoclonal antibodies for migraine: rationale and progress. BioDrugs 2017;31:487-501 28. Tepper SJ History and review of anti- Calcitonin Gene-Related Peptide (CGRP) therapies: From translational research to treatment. Headache 2018;58:Suppl 3:238- 75 29. Shi L et al. Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the Calcitonin Gene-Related Peptide Receptor. J Pharmacol Exp Ther 2016;356:223-31 30. Goadsby PJ et al. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990:28:183-7 31. Cernuda-Morollon E et al. Interictal increase of CGRP levels in peripheral blood as a biomarker for chronic migraine. Neurology 2013;81:1191-6 32. Lassen LH et al. CGRP may play a causative role in migraine. Cephalalgia 2002;22:54-61 33. Goadsby PJ et al. The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol 1993;33:48-56 34. Olesen J et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004;350:1104-10 35. Ho TW et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology 2014;83:958-66 36. Goadsby PJ et al. A controlled trial of Erenumab for episodic migraine. N Engl J Med 2017;377:2123-32 37. Tepper S et al. Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double- blind, placebo-controlled phase 2 trial. Lancet Neurol 2017;16:425-34 38. Reuter U et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo- controlled, phase 3b study. Lancet 2018;392:2280-7 39. 40. Depre C et al. A randomized, double-blind, placebo-controlled study to evaluate the effect of Erenumab on exercise time during a treadmill test in patients with stable angina. Headache 2018;58:715-23 41. Göbel H et al. Gesundheitsverhalten von Migräne- und Kopfschmerzpatienten bei digitaler Therapiebegleitung mit der Migräne-App. Schmerz 2019;33:147-55 42. Schwedt T et al. Early onset of efficacy with erenumab in patients with episodic and chronic migraine. J Headache Pain 2018;19:92 43. Ashina M et al. Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study. Neurology 2017;89:1237-43 44. downloads/92-975-2734/2018-11-01_ Nutzenbewertung-IQWiG_ Erenumab-D-407.pdf. 45. Diener HC et al. Therapie der Migräneattacke und Prophylaxe der Migräne, S1-Leitlinie 2018. In: Deutsche Gesellschaft für Neurologie (Hrsg.) Leitlinien für Diagnostik und Therapie in der Neurologie. Online: leitlinien 46. Göbel H et al. Chronic migraine and headache by medication overuse. Evolution and revision of classification. Schmerz 2011;25:493-500 Deutsche Gesellschaft für Schmerzmedizin e. V. Schmerzmedizin 2019; 35 (3) 45